Enrique Carmona-Montesinos

Enrique Carmona-Montesinos


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LCLABORATORIOS COLUMBIA COMERCIAL
LABORATORIOS COLUMBIA COMERCIAL
ECEnrique Carmona-Montesinos
Enrique Carmona-Montesinos
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
ICIsrael Campos
Israel Campos
Juan Carlos Castillo SalinasJuan Carlos Castillo Salinas
Juan Carlos Castillo Salinas
EREdgar Ramirez-Ramirez
Edgar Ramirez-Ramirez
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.

12 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LCLABORATORIOS COLUMBIA COMERCIAL
LABORATORIOS COLUMBIA COMERCIAL
ECEnrique Carmona-Montesinos
Enrique Carmona-Montesinos
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
ICIsrael Campos
Israel Campos
Juan Carlos Castillo SalinasJuan Carlos Castillo Salinas
Juan Carlos Castillo Salinas
EREdgar Ramirez-Ramirez
Edgar Ramirez-Ramirez
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.